Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX)

Virpax’s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA) with the National Institute of Health/NCATS and U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated treatment options, targeting unmet global needs in multi-billion-dollar markets. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)